So the drug companies' $1.32 billion estimate was off, according to Light and Warburton, by only $977 million. Let's call it a rounding error.
Better buys time, not a barrier: what counter-positioning means for your
patent strategy
-
A better product buys a challenger time. It does not buy a barrier. The
mistake most founders make is treating the time as the win, and spending
the whole ...
2 days ago

No comments:
Post a Comment